ReviewVaccines2025
Clinical Translation Challenges and Strategies for Tumour Vaccines Considering Multiple Delivery Routes.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rational Design and Responsive Transdermal Cargo Delivery of Microneedles in the Treatment of Melanoma.International journal of nanomedicine · 2026Review
- Melanoma vaccines: current R&D landscape, translational hurdles, and future outlook-a perspective drawn from 442 clinical trials.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe high incidence and mortality rates of cancer have kept it at the top of the research agenda for the global healthcare industry, as well as put serious economic pressure on families and society. It has gradually been recognised that reducing the incidence of cancer through various interventions and that combining prevention and treatment are the key to alleviating the burden of cancer.
methodsRetrieve and summarize the literature related to the delivery methods of tumor vaccines, and investigate whether these delivery methods have been applied clinically or have been used in clinical trials.
resultsthere are a variety of methods for cancer vaccine development, but only a very small number of studies have been able to make strides towards implementing these methods in the clinic, which is closely linked to drawbacks with the means of vaccine delivery.
conclusionsThis review analyses the reasons why it is difficult to apply these methods in the clinic from the point of view of the delivery method rather than the design of the cancer vaccine. It also describes some of the delivery methods that have not yet been applied for cancer vaccines and, considering this in conjunction with those that are currently used for this purpose, predicts their prospects for future application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.